Search

Your search keyword '"Mens, Jan-Willem M."' showing total 34 results
Start Over Author "Mens, Jan-Willem M."
34 results on '"Mens, Jan-Willem M."'

1. Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials

Author

Wakkerman, Famke C, Wu, Jiqing, Putter, Hein, Jürgenliemk-Schulz, Ina M, Jobsen, Jan J, Lutgens, Ludy C H W, Haverkort, Marie A D, de Jong, Marianne A, Mens, Jan Willem M, Wortman, Bastiaan G, Nout, Remi A, Léon-Castillo, Alicia, Powell, Melanie E, Mileshkin, Linda R, Katsaros, Dionyssios, Alfieri, Joanne, Leary, Alexandra, Singh, Naveena, de Boer, Stephanie M, Nijman, Hans W, Smit, Vincent T H B M, Bosse, Tjalling, Koelzer, Viktor H, Creutzberg, Carien L, and Horeweg, Nanda

Published
2024
Full Text
View/download PDF

2. Overall survival after definitive chemoradiotherapy for patients with esophageal cancer: a retrospective cohort study

Author

van der Zijden, Charlène J, primary, Bouwman, Anna, additional, Mostert, Bianca, additional, Nuyttens, Joost J M E, additional, van der Sluis, Pieter C, additional, Spaander, Manon C W, additional, Mens, Jan Willem M, additional, Homs, Marjolein Y V, additional, van Doorn, Leni, additional, Wijnhoven, Bas P L, additional, and Lagarde, Sjoerd M, additional

Published
2024
Full Text
View/download PDF

4. Age-Related Differences in Patient Preferences for Adjuvant Chemotherapy for High-Risk Endometrial Cancer

Author

Wakkerman, Famke C., primary, Post, Cathalijne C.B., additional, Mens, Jan-Willem M., additional, Jurgenliemk-Schulz, Ina, additional, Koppe, Friederike, additional, Haverkort, Marie A.D., additional, Roeloffzen, Ellen M.A., additional, Snyers, An, additional, de Jong, Marianne A.A., additional, Schaake, Eva E., additional, Beukema, Jannet C., additional, Cnossen, Jeltsje S., additional, Kiderlen, Mandy, additional, Lutgens, Ludy CHW, additional, Nijman, Hans W., additional, D de Kroon, Cornelis, additional, Kroep, Judith R., additional, Pieterse, Arwen H., additional, Creutzberg, Carien L., additional, and Horeweg, Nanda, additional

Published
2024
Full Text
View/download PDF

5. Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making

Author

Post, Cathalijne C.B., Mens, Jan Willem M., Haverkort, Marie A.D., Koppe, Friederike, Jürgenliemk-Schulz, Ina M., Snyers, An, Roeloffzen, Ellen M.A., Schaake, Eva E., Slot, Annerie, Stam, Tanja C., Beukema, Jannet C., van den Berg, Hetty A., Lutgens, Ludy C.H.W., Nijman, Hans W., de Kroon, Cornelis D., Kroep, Judith R., Stiggelbout, Anne M., and Creutzberg, Carien L.

Published
2021
Full Text
View/download PDF

7. Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, -2 and -3 trials

Author

Wakkerman, Famke Charlotte, primary, Wu, Jiqing, additional, Putter, Hein, additional, Jurgenliemk-Schulz, Ina M., additional, Jobsen, Jan J., additional, Lutgens, Ludy C.H.W., additional, Haverkort, Marie A.D., additional, de Jong, Marianne, additional, Mens, Jan Willem M., additional, Wortman, Bastiaan G., additional, Nout, Remi A., additional, Leon-Castillo, Alicia, additional, Powell, Melanie E., additional, Mileshkin, Linda R., additional, Katsaros, Dionyssios, additional, Alfieri, Joanne, additional, Leary, Alexandra, additional, Singh, Naveena, additional, de Boer, Stephanie M., additional, Nijman, Hans W., additional, Smit, Vincent T.H.B.M., additional, Bosse, Tjalling, additional, Koelzer, Viktor H., additional, Creutzberg, Carien L., additional, and Horeweg, Nanda, additional

Published
2023
Full Text
View/download PDF

9. Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.

Author

Horeweg, Nanda, Nout, Remi A., Jürgenliemk-Schulz, Ina M., Lutgens, Ludy C.H.W., Jobsen, Jan J., Haverkort, Marie A.D., Mens, Jan Willem M., Slot, Annerie, Wortman, Bastiaan G., de Boer, Stephanie M., Stelloo, Ellen, Verhoeven-Adema, Karen W., Putter, Hein, Smit, Vincent T.H.B.M., Bosse, Tjalling, Creutzberg, Carien L., Creutzberg, C.L., Koper, P.C.M., van Putten, W.L.J., and Dercksen, R.

Published
2023
Full Text
View/download PDF

11. Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial

Author

de Boer, Stephanie M., Nout, Remi A., Jürgenliemk-Schulz, Ina M., Jobsen, Jan J., Lutgens, Ludy C.H.W., van der Steen-Banasik, Elzbieta M., Mens, Jan Willem M., Slot, Annerie, Stenfert Kroese, Marika C., Oerlemans, Simone, Putter, Hein, Verhoeven-Adema, Karen W., Nijman, Hans W., and Creutzberg, Carien L.

Published
2015
Full Text
View/download PDF

13. 2022-RA-825-ESGO The impact of age on prognosis in women with endometrial cancer: a pooled analysis of the PORTEC-1, -2 and -3 randomised trials

Author

Wakkerman, Famke Charlotte, primary, De Boer, Stephanie M, additional, Powell, Melanie E, additional, Leary, Alexandra, additional, Fyles, Anthony, additional, Mileshkin, Linda R, additional, Singh, Naveena, additional, Nout, Remi A, additional, Jürgenliemk-Schulz, Ina M, additional, Jobsen, Jan J, additional, Lutgens, Ludy CHW, additional, van der Steen-Banasik, Elsbieta M, additional, Mens, Jan-Willem M, additional, Slot, Annerie, additional, Nijman, Hans W, additional, Smit, Vincent THBM, additional, Bosse, Tjalling, additional, Creutzberg, Carien L, additional, and Horeweg, Nanda, additional

Published
2022
Full Text
View/download PDF

14. 2022-RA-450-ESGO Benefit of adjuvant radiotherapy depends on molecular class of early-stage endometrial cancer

Author

Horeweg, Nanda, primary, Nout, Remi A, additional, Stelloo, Ellen, additional, Lutgens, Ludy CHW, additional, Jobsen, Jan J, additional, Jürgenliemk-Schulz, Ina M, additional, van der Steen-Banasik, Elsbieta M, additional, Mens, Jan-Willem M, additional, Slot, Annerie, additional, Smit, Vincent THBM, additional, Bosse, Tjalling, additional, and Creutzberg, Carien L, additional

Published
2022
Full Text
View/download PDF

16. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data

Author

Nout, Remi A., Putter, Hein, Jürgenliemk-Schulz, Ina M., Jobsen, Jan J., Lutgens, Ludy C.H.W., van der Steen-Banasik, Elzbieta M., Mens, Jan Willem M., Slot, Annerie, Stenfert Kroese, Marika C., Nijman, Hans W., van de Poll-Franse, Lonneke V., and Creutzberg, Carien L.

Published
2012
Full Text
View/download PDF

18. PROTECT: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System

Author

Corbeau, Anouk, primary, Nout, Remi A., additional, Mens, Jan Willem M., additional, Horeweg, Nanda, additional, Godart, Jérémy, additional, Kerkhof, Ellen M., additional, Kuipers, Sander C., additional, van Poelgeest, Mariette I. E., additional, Kroep, Judith R., additional, Boere, Ingrid A., additional, van Doorn, Helena C., additional, Hoogeman, Mischa S., additional, van der Heide, Uulke A., additional, Putter, Hein, additional, Welters, Marij J. P., additional, van der Burg, Sjoerd H., additional, Creutzberg, Carien L., additional, and de Boer, Stephanie M., additional

Published
2021
Full Text
View/download PDF

20. Defining Substantial Lymphovascular Space Invasion in Endometrial Cancer

Author

Peters, Elke E.M., primary, León-Castillo, Alicia, additional, Smit, Vincent T.H.B.M., additional, Boennelycke, Marie, additional, Hogdall, Estrid, additional, Hogdall, Claus, additional, Creutzberg, Carien, additional, Jürgenliemk-Schulz, Ina M., additional, Jobsen, Jan J., additional, Mens, Jan Willem M., additional, Lutgens, Ludy C.H.W., additional, van der Steen-Banasik, Elzbieta M., additional, Ortoft, Gitte, additional, Bosse, Tjalling, additional, and Nout, Remi, additional

Published
2021
Full Text
View/download PDF

22. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer

Author

van den Heerik, Anne Sophie V M, primary, Horeweg, Nanda, additional, Nout, Remi A, additional, Lutgens, Ludy C H W, additional, van der Steen-Banasik, Elzbieta M, additional, Westerveld, G Henrike, additional, van den Berg, Hetty A, additional, Slot, Annerie, additional, Koppe, Friederike L A, additional, Kommoss, Stefan, additional, Mens, Jan Willem M, additional, Nowee, Marlies E, additional, Bijmolt, Stefan, additional, Cibula, David, additional, Stam, Tanja C, additional, Jurgenliemk-Schulz, Ina M, additional, Snyers, An, additional, Hamann, Moritz, additional, Zwanenburg, Aleida G, additional, Coen, Veronique L M A, additional, Vandecasteele, Katrien, additional, Gillham, Charles, additional, Chargari, Cyrus, additional, Verhoeven-Adema, Karen W, additional, Putter, Hein, additional, van den Hout, Wilbert B, additional, Wortman, Bastiaan G, additional, Nijman, Hans W, additional, Bosse, Tjalling, additional, and Creutzberg, Carien L, additional

Published
2020
Full Text
View/download PDF

24. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3) : final results of an international, open-label, multicentre, randomised, phase 3 trial

Author

de Boer, Stephanie M., Powell, Melanie E., Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Petronella B., Ledermann, Jonathan A., Khaw, Pearly, Colombo, Alessandro, Fyles, Anthony, Baron, Marie Helene, Jürgenliemk-Schulz, Ina M., Kitchener, Henry C., Nijman, Hans W., Wilson, Godfrey, Brooks, Susan, Carinelli, Silvestro, Provencher, Diane, Hanzen, Chantal, Lutgens, Ludy C.H.W., Smit, Vincent T.H.B.M., Singh, Naveena, Do, Viet, D'Amico, Romerai, Nout, Remi A., Feeney, Amanda, Verhoeven-Adema, Karen W., Putter, Hein, Creutzberg, Carien L., McCormack, Mary, Whitmarsh, Karen, Allerton, Rozenn, Gregory, Deborah, Symonds, Paul, Hoskin, Peter J., Adusumalli, Madhavi, Anand, Anjana, Wade, Robert, Stewart, Alexandra, Taylor, Wendy, Kruitwagen, Roy F.P.M., Hollema, Harry, Pras, Elizabeth, Snyers, An, Stalpers, Lukas, Jobsen, Jan J., Slot, Annerie, Mens, Jan Willem M., and Stam, Tanja C.

Subjects
Canada, Time Factors, Endometrial Neoplasms/mortality, Clinical Trial, Phase III, Risk Factors, Paclitaxel/administration & dosage, Journal Article, Humans, Comparative Study, Aged, Neoplasm Staging, Gynecologic Surgical Procedures/adverse effects, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Research Support, Non-U.S. Gov't, Australia, Carboplatin/administration & dosage, Chemoradiotherapy, Adjuvant/adverse effects, Middle Aged, Europe, Multicenter Study, Treatment Outcome, Oncology, Randomized Controlled Trial, Carcinoma, Endometrioid/mortality, Lymph Node Excision, Female, Radiotherapy, Adjuvant, Dose Fractionation, Radiation, Neoplasm Grading, Cisplatin/administration & dosage, New Zealand
Abstract

BACKGROUND: Although women with endometrial cancer generally have a favourable prognosis, those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 trial was initiated to investigate the benefit of adjuvant chemotherapy during and after radiotherapy (chemoradiotherapy) versus pelvic radiotherapy alone for women with high-risk endometrial cancer. METHODS: PORTEC-3 was an open-label, international, randomised, phase 3 trial involving 103 centres in six clinical trials collaborating in the Gynaecological Cancer Intergroup. Eligible women had high-risk endometrial cancer with FIGO 2009 stage I, endometrioid-type grade 3 with deep myometrial invasion or lymph-vascular space invasion (or both), endometrioid-type stage II or III, or stage I to III with serous or clear cell histology. Women were randomly assigned (1:1) to receive radiotherapy alone (48·6 Gy in 1·8 Gy fractions given on 5 days per week) or radiotherapy and chemotherapy (consisting of two cycles of cisplatin 50 mg/m 2 given during radiotherapy, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m 2) using a biased-coin minimisation procedure with stratification for participating centre, lymphadenectomy, stage of cancer, and histological type. The co-primary endpoints were overall survival and failure-free survival. We used the Kaplan-Meier method, log-rank test, and Cox regression analysis for final analysis by intention to treat and adjusted for stratification factors. The study was closed on Dec 20, 2013, after achieving complete accrual; follow-up is ongoing. PORTEC-3 is registered with ISRCTN, number ISRCTN14387080, and ClinicalTrials.gov, number NCT00411138. RESULTS: 686 women were enrolled between Nov 23, 2006, and Dec 20, 2013. 660 eligible patients were included in the final analysis, of whom 330 were assigned to chemoradiotherapy and 330 were assigned to radiotherapy. Median follow-up was 60·2 months (IQR 48·1-73·1). 5-year overall survival was 81·8% (95% CI 77·5-86·2) with chemoradiotherapy versus 76·7% (72·1-81·6) with radiotherapy (adjusted hazard ratio [HR] 0·76, 95% CI 0·54-1·06; p=0·11); 5-year failure-free survival was 75·5% (95% CI 70·3-79·9) versus 68·6% (63·1-73·4; HR 0·71, 95% CI 0·53-0·95; p=0·022). Grade 3 or worse adverse events during treatment occurred in 198 (60%) of 330 who received chemoradiotherapy versus 41 (12%) of 330 patients who received radiotherapy (p

Published
2018

27. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer – A pooled analysis of PORTEC 1 and 2 trials

Author

Bosse, Tjalling, primary, Peters, Elke E.M., additional, Creutzberg, Carien L., additional, Jürgenliemk-Schulz, Ina M., additional, Jobsen, Jan J., additional, Mens, Jan Willem M., additional, Lutgens, Ludy C.H.W., additional, van der Steen-Banasik, Elzbieta M., additional, Smit, Vincent T.H.B.M., additional, and Nout, Remi A., additional

Published
2015
Full Text
View/download PDF

30. Long-Term Outcome and Quality of Life of Patients With Endometrial Carcinoma Treated With or Without Pelvic Radiotherapy in the Post Operative Radiation Therapy in Endometrial Carcinoma 1 (PORTEC-1) Trial

Author

Nout, Remi A., primary, van de Poll-Franse, Lonneke V., additional, Lybeert, Marnix L.M., additional, Wárlám-Rodenhuis, Carla C., additional, Jobsen, Jan J., additional, Mens, Jan Willem M., additional, Lutgens, Ludy C.H.W., additional, Pras, Betty, additional, van Putten, Wim L.J., additional, and Creutzberg, Carien L., additional

Published
2011
Full Text
View/download PDF

31. Quality of Life After Pelvic Radiotherapy or Vaginal Brachytherapy for Endometrial Cancer: First Results of the Randomized PORTEC-2 Trial

Author

Nout, Remi A., primary, Putter, Hein, additional, Jürgenliemk-Schulz, Ina M., additional, Jobsen, Jan J., additional, Lutgens, Ludy C.H.W., additional, van der Steen-Banasik, Elzbieta M., additional, Mens, Jan Willem M., additional, Slot, Annerie, additional, Stenfert Kroese, Marika C., additional, van Bunningen, Bart N.F.M., additional, Smit, Vincent T.H.B.M., additional, Nijman, Hans W., additional, van den Tol, Philine P., additional, and Creutzberg, Carien L., additional

Published
2009
Full Text
View/download PDF

34. Efficacy of a nurse-led sexual rehabilitation intervention for women with gynaecological cancers receiving radiotherapy: results of a randomised trial.

Author

Suvaal I, Hummel SB, Mens JM, Tuijnman-Raasveld CC, Tsonaka R, Velema LA, Westerveld H, Cnossen JS, Snyers A, Jürgenliemk-Schulz IM, Lutgens LCHW, Beukema JC, Haverkort MAD, Nowee ME, Nout RA, de Kroon CD, van den Hout WB, Creutzberg CL, van Doorn HC, and Ter Kuile MM

Abstract

Background: The multicentre randomised SPARC trial evaluated the efficacy of a nurse-led sexual rehabilitation intervention on sexual functioning, distress, dilator use, and vaginal symptoms after radiotherapy for gynaecological cancers., Methods: Eligible women were randomised to the rehabilitation intervention or care-as-usual. Four intervention sessions were scheduled over 12 months, with concurrent validated questionnaires and clinical assessments. Primary outcome was the Female Sexual Function Index (FSFI). A generalised-mixed-effects model compared groups over time., Results: In total, 229 women were included (n = 112 intervention; n = 117 care-as-usual). No differences in FSFI total scores were found between groups at any timepoint (P = 0.37), with 12-month scores of 22.57 (intervention) versus 21.76 (care-as-usual). The intervention did not significantly improve dilator use, reduce sexual distress or vaginal symptoms compared to care-as-usual. At 12 months, both groups had minimal physician-reported vaginal stenosis; 70% of women were sexually active and reported no or mild vaginal symptoms. After radiotherapy and brachytherapy, 85% (intervention) versus 75% (care-as-usual) of participants reported dilation twice weekly., Discussion: Sexual rehabilitation for women treated with combined (chemo)radiotherapy and brachytherapy improved before and during the SPARC trial, which likely contributed to comparable study groups. Best practice involves a sexual rehabilitation appointment 1 month post-radiotherapy, including patient information, with dilator guidance, preferably by a trained nurse, and follow-up during the first year after treatment., Clinical Trial Registration: NCT03611517., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results